DOI:
10.1055/s-00000173
Neuroradiologie Scan
LinksClose Window
References
Weller M, Tabatabai G, Kästner B. et al.
MGMT promoter methylation is a strong prognostic biomarker for benefit from doseintensified temozolomide rechallenge in progressive glioblastoma: the DIRECTOR trial.
Clin Cancer Res 2015;
21: 2057-2064
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.